Cosmo announces launch of Winlevi® for Treatment of Acne in Singapore and Malaysia

Dublin, Ireland – July 17, 2025: Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with Hyphens Pharma International Limited ("Hyphens Pharma"). Winlevi® is a topical treatment for acne vulgaris in patients aged twelve years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.

Winlevi® is the first topical acne treatment in over 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor acting directly in the sebaceous glands with no systemic anti-androgen effects; as such, it can be used safely in both males and females. This approach is believed to help reduce sebum production and intervene early in acne pathogenesis. Two identical Phase III studies demonstrated that clascoterone cream 1%, applied topically twice daily for twelve weeks, was more effective than the application of vehicle cream in achieving the Investigator's Global Assessment (IGA) of success, reducing non-inflammatory lesion count (NILC) and inflammatory lesion count (ILC) in patients with facial acne vulgaris. Clascoterone cream 1% was found to be generally well tolerated.

As part of the agreement signed in December 2022, Hyphens Pharma has in-licensed the product from Cosmo Pharmaceuticals for distribution across ten Southeast Asian countries (Singapore, Malaysia, Indonesia, Philippines, Vietnam, Thailand, Brunei, Cambodia, Laos and Myanmar), bringing this innovative therapy first to Singapore and Malaysia markets. Registration in other Southeast Asian markets is currently underway, with a progressive rollout planned across the region in due course. This collaboration underscores the dedication of Cosmo and Hyphens Pharma to expanding its dermatology portfolio and addressing the unmet needs of patients with acne vulgaris, a condition that affects millions of individuals worldwide and can cause both physical discomfort and psychological distress.

Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented: *"The launch of Winlevi® in Southeast Asia is an important step in our ongoing global expansion and directly supports our 2030 vision of driving sustainable revenue growth through strategic geographic expansion. Together with Hyphens Pharma, we are bringing a truly differentiated dermatology innovation to a rapidly growing market with increasing demand for advanced acne care. This partnership demonstrates tangible progress in executing our long-term growth strategy and underscores our shared commitment to addressing unmet medical needs while delivering meaningful impact for patients across Asia."*

Lim See Wah (林世华), Executive Chairman and CEO of Hyphens Pharma, added: *"We're proud to be the first to introduce Winlevi® to Southeast Asia. Acne affects millions in the region, yet for decades, patients have had limited treatment options. This launch marks a significant advancement in acne care, our dermatology portfolio and partnership with Cosmo. We appreciate their trust in us to bring this transformative treatment to the region. Acne isn't just skin-deep – it can impact psychosocial well-being.*

By expanding access to Winlevi®, we aim to support doctors in their practice and empower patients to manage acne with greater confidence, improving their quality of life."

Acne vulgaris is one of the most common skin conditions, impacting more than 90% of the world's population at some point in their lives. It can have both physical and emotional consequences, affecting individuals' self-esteem and mental health.

About Hyphens Pharma International Limited

Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 15 other markets – Bangladesh, Brunei, Cambodia, Hong Kong S.A.R., Macau S.A.R., Myanmar, South Korea, Sri Lanka, Thailand and Gulf Cooperation Council countries, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates. The Group is headquartered in Singapore, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group's core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online pharmacy for doctors to prescribe and have medications delivered to their patients' homes. For more information, visit www.hyphensgroup.com

About Cosmo

Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit www.cosmohealthconfidence.com

Financial calendar

Half-Year 2025 Results and Report	July 23, 2025
H.C. Wainwright 27th Annual Global Investment Conference, New York City, USA	September 8-10, 2025
Jefferies Global Healthcare Conference, London, United Kingdom	November 17-20, 2025
ODDO BHF Forum, Lyon, France	January 8-9, 2026

For further information, please contact:

investor.relations@cosmohc.com